Sept 27 (Reuters) - Sanofi (PA:SASY) Canada:
* HEALTH CANADA APPROVES DUPIXENT™ AS THE FIRST BIOLOGIC FOR THE TREATMENT OF ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
* HEALTH CANADA APPROVES DUPIXENT FOR TREATMENT OF ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS